Benefits
DashboardNot registered yet? Get a free account.
Sign UpNot registered yet? Get a free account.
Sign Up
You're about to leave our website and go to an external link. Are you sure?
Bharat Serums And Vaccines Limited, is an unlisted public company incorporated on 11 November, 1993. It is classified as a public limited company and is located in Thane, Maharashtra. It's authorized share capital is INR 352.16 cr and the total paid-up capital is INR 73.09 lac.
Bharat Serums And Vaccines Limited's operating revenue range is Over INR 500 cr for the financial year ending on 31 March, 2023. It's EBITDA has decreased by 25.35% over the previous year. At the same time, it's book networth has increased by 13.49%.
Read more
Buy Dashboard using Credits
This action will use 1 of your credits. Are you sure you want to go ahead?
Credits Balance:
0
** All rupee values in INR crores. Based on March 2024 numbers.
18.13%
51.86%
420.76%
2.26%
-8.39%
1.21%
0.32
4.03
2.64
1.08
2.72
-0.03
Buy Report or Plans
Company dashboard
Five year financials and ratios
Risk analysis
Interactive charts
All financials
All annual returns
MoA and AoA
Latest financials
Latest annual return
MoA and AoA
Five year financials and ratios
Shareholding and group structure
Litigation and more
Everything in financial report
Peers and financials
* GST not included
** Reports & MCA filings will be based on the latest available financials.
India
(27)
| State | Type | Address |
|---|
Locations on Map
Filter (4)
Severe Risk
Moderate Risk
Low Risk
Read more
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| Sales | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating profit | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net profit | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Gross margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Networth | |||||
| Borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Debt to equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Current ratio | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| ROE | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days payable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| WC days | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| Equity Capital | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Reserves | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Borrowings + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Long term borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Short term borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Trade payables + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days payable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other liabilities + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other non-current liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other current liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Fixed Assets + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Tangible assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| CWIP | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Intangible assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| LT loans and advances | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other non-current assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Current assets + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Inventories | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Trade receivables | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Cash and cash equivalents | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| ST loans and advances | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other current assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| Sales + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Sales growth % | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Expenses + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Cost of goods | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Employee cost | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other costs | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating profit + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating margin % | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other income | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Interest | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Depreciation | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Exceptional items | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Profit before tax | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Tax | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Profit - disc. ops | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net profit | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net margin % | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| Solvency + | |||||
| Total Debt/Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net Debt/Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total Debt/Assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total Assets/Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Liquidity + | |||||
| Current Ratio | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Quick Ratio | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Interest Coverage | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Performance | |||||
| Gross Margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating Margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net Margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Return + | |||||
| Return on Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Pre-tax ROCE | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Return on Assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Pre-tax ROIC | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Efficiency + | |||||
| Days Payable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days Inventory | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days Receivable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Fixed Asset Turnover | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total Asset Turnover | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Working Capital | |||||
| Cash Conversion Cycle | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Working Capital Days | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
ICICI Bank Limited
No. of Loans: 1
Total Amount : 85.0 cr
Axis Bank Limited
No. of Loans: 1
Total Amount : 65.0 cr
IDBI Bank Limited
No. of Loans: 1
Total Amount : 35.0 cr
The Hongkong and Shanghai Banking Corporation Limited
No. of Loans: 1
Total Amount : 25.0 cr
CitiBank N.A.
No. of Loans: 1
Total Amount : 25.0 cr
DBS BANK INDIA LIMITED
No. of Loans: 1
Total Amount : 25.0 cr
HDFC Bank Limited
No. of Loans: 1
Total Amount : 6.0 cr
| Designation | Name | DIN/PAN | Tenure |
|---|---|---|---|
| Director | Shweta Jalan | 00291675 | 3 years |
| Director | Bhaskar Vemban Iyer
Shareholder
|
00480341 | 3 years |
| Director | Jayesh Tulsidas Merchant | 00555052 | 3 years |
| CFO | Chirag Ashokbhai Mehta | <HIDDEN> | 3 years |
| Managing Director | Sanjiv Hari Navangul | 02924640 | 5 years |
| CS | Anupama Diwakar Pai | <HIDDEN> | 3 years |
| Director | Pankaj Patwari | 08206620 | 5 years |
| Director | Abhijit Mangalmoy Mukherjee
Shareholder
|
08610857 | 3 years |
| Name | Status | Paid up Capital | Common Directors | Address |
|---|---|---|---|---|
| YES BANK LIMITED |
Active
|
6,269.4 Cr | 1 | Maharashtra |
| SUVEN PHARMACEUTICALS LIMITED |
Active
|
25.5 Cr | 2 | Telangana |
| COHANCE LIFESCIENCES LIMITED |
Active
|
3,394.7 Cr | 4 | Maharashtra |
| BHARAT SERUMS AND VACCINES LIMITED |
Amalgamated
|
9.0 Cr | 8 | Maharashtra |
| ZCL CHEMICALS LIMITED |
Amalgamated
|
9.1 Cr | 4 | Maharashtra |
| RA CHEM PHARMA LIMITED |
Amalgamated
|
8.5 Cr | 4 | Andhra Pradesh |
| MANJUSHREE TECHNOPACK LIMITED |
Active
|
13.7 Cr | 2 | Karnataka |
| MODENIK LIFESTYLE PRIVATE LIMITED |
Active
|
34.4 Cr | 1 | Karnataka |
| THEMIS MEDICARE LIMITED |
Active
|
9.2 Cr | 1 | Gujarat |
| RPG LIFE SCIENCES LIMITED |
Active
|
13.2 Cr | 1 | Maharashtra |
| TATA INVESTMENT CORPORATION LIMITED |
Active
|
50.6 Cr | 1 | Maharashtra |
| QUASAR CONSOLIDATED SERVICES PRIVATE LIMITED |
Active
|
3.0 L | 1 | Maharashtra |
| KOTAK MAHINDRA TRUSTEE COMPANY LIMITED |
Active
|
5.0 L | 1 | Maharashtra |
| JUSTLEGAL CORPORATE ADVISORS PRIVATE LIMITED |
Strike Off
|
1.0 L | 1 | Maharashtra |
| NEXUS SELECT MALL MANAGEMENT PRIVATE LIMITED |
Active
|
15.0 Cr | 1 | Maharashtra |
| VOLTAS LIMITED |
Active
|
33.1 Cr | 1 | Maharashtra |
| TRENT LIMITED |
Active
|
35.5 Cr | 1 | Maharashtra |
| LENSKART SOLUTIONS PRIVATE LIMITED |
Active
|
182.5 Cr | 1 | Delhi |
| BSVLIFE PRIVATE LIMITED |
Amalgamated
|
1.0 Cr | 1 | Maharashtra |
| KEIMED PRIVATE LIMITED |
Active
|
6.8 Cr | 1 | Telangana |
| GOKALDAS INTIMATEWEAR PRIVATE LIMITED |
Amalgamated
|
30.5 Cr | 1 | Karnataka |
| APOLLO HEALTHCO LIMITED |
Active
|
2,884.9 Cr | 1 | Tamil Nadu |
| ADVENT INDIA PE ADVISORS PRIVATE LIMITED |
Active
|
2.2 Cr | 1 | Maharashtra |
| Name | State / Country | Incorporation Year | Paidup Capital |
|---|---|---|---|
| BSV PHARMA PRIVATE LIMITED | India | - | - |
| BSV Bioscience GmbH | Germany | - | - |
| BSV Biosciences Inc. | United States | - | - |
| BSV Bioscience Malaysia Sdn. Bhd. | Malaysia | - | - |
| Genomicks Sdn. Bhd. | Malaysia | - | - |
| BSV Bioscience Philippines Inc. | Philippines | - | - |
The incorporation date of BHARAT SERUMS AND VACCINES LIMITED is 11 November, 1993
The authorized share capital of BHARAT SERUMS AND VACCINES LIMITED is INR ₹ 352.2 Cr.
The paid-up capital of BHARAT SERUMS AND VACCINES LIMITED is INR ₹ 73.1 L.
The registered address of BHARAT SERUMS AND VACCINES LIMITED is 3rd Floor, Liberty Tower, Plot No. K-10, Behind Reliable Pla za, Kalwa Industrial Estate, Airoli Thane Thane Maharashtra - 400708
The CIN number of BHARAT SERUMS AND VACCINES LIMITED is U74110MH1993PLC075088.
Expand
Delete
Collapse
See
details
